Lannett Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record Revenues, Strong Earnings

--Adjusted EPS Higher Than Expected; Full-Year Adjusted Profitability Expected to Improve--

PHILADELPHIA, Feb. 7, 2018 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2018 second quarter ended December 31, 2017. 

Lannett Logo (PRNewsFoto/Lannett Company, Inc.)

"Our record revenues for the second quarter reflect strong sales across several product categories," said Tim Crew, Lannett's recently appointed chief executive officer.  "Our topline increased 19% from the preceding quarter and would have been even higher, but for the shorter than anticipated supply disruption for a key product by a competitor. 

"With regard to our fiscal 2018 second quarter bottomline, our adjusted earnings substantially benefited from recently enacted U.S. tax reform.  We also anticipate our future results will be positively impacted by a lower effective tax rate.  

"Looking ahead, we recently commenced shipping an authorized generic version of Toprol-XL® (Metoprolol Succinate) Extended Release Tablets and expect over the next several months to launch a number of products, which include previously approved, as well as recently acquired or licensed, commercially ready products.  While we have revised several components of our outlook, we expect our profitability on an adjusted basis for the fiscal 2018 full year to slightly improve from our previous guidance." 

For the fiscal 2018 second quarter, net sales were $184.3 million compared with $170.9 million for the second quarter of fiscal 2017.  Gross profit was $87.5 million, or 47% of net sales, compared with $88.1 million, or 52% of net sales.  Research and development (R&D) expenses increased to $10.7 million from $9.9 million for the fiscal 2017 second quarter.  Selling, general and administrative (SG&A) expenses increased to $28.5 million from $18.1 million.  Restructuring expenses were $1.0 million compared with $1.7 million.  In the prior year second quarter, the company recorded an impairment charge of $23.0 million related to an acquired in-process R&D project.  Operating income increased 37% to $47.1 million from $34.3 million.  Interest expense declined to $20.7 million from $23.3 million for the second quarter of fiscal 2017.  Income tax expense was $18.1 million compared with $3.5 million in the prior-year period.  Net income attributable to Lannett was $14.0 million, or $0.37 per diluted share, compared with $8.2 million, or $0.22 per share, for the fiscal 2017 second quarter. 

For the fiscal 2018 second quarter reported on a Non-GAAP basis, adjusted net sales were $184.3 million compared with $170.9 million for the second quarter of fiscal 2017.  Adjusted gross profit was $96.7 million, or 52% of adjusted net sales, compared with $96.2 million, or 56% of adjusted net sales, for the prior year second quarter.  Adjusted R&D expenses were $10.7 million compared with $9.9 million.  Adjusted SG&A expenses were $20.9 million compared with $17.0 million.  Adjusted operating income was $65.1 million compared with $69.3 million for the prior-year second quarter.  Adjusted interest expense declined to $16.2 million from $17.9 million for the second quarter of fiscal 2017.  Adjusted income tax expense was $10.5 million compared with $17.5 million in the prior-year period.  Adjusted net income attributable to Lannett was $40.6 million, or $1.06 per diluted share, compared with $34.5 million, or $0.92 per diluted share, for the fiscal 2017 second quarter.

Guidance for Fiscal 2018
Based on its current outlook, the company revised its 2018 fiscal year financial guidance from November 6, 2017.  The revised guidance for net sales and profitability is higher than the guidance provided on August 23, 2017, which did not include the impact of the supply disruption for a key product mentioned above.


GAAP

Non-GAAP Adjusted

Net sales

$680 million to $700 million, down from 710 million to $720 million

$680 million to $700 million, down from $710 million to $720 million

Gross margin %

42% to 43%, down from 46% to 47%

48% to 49%, down from 51% to 52%

R&D expense

$36 million to $38 million, down from $46 million to $48 million

$36 million to $38 million, down from $46 million to $48 million

SG&A expense

$79 million to $81 million, up from $78 million to $80 million

$71 million to $73 million, down from $77 million to $79 million

Integration and restructuring related expense

$4 million to $5 million, unchanged

$ --

Interest expense and other

$77 million to $78 million, down from $85 million to $86 million

$62 million to $63 million, down from $66 million to $67 million

Effective tax rate

Approximately 39%, up from 35%

Approximately 27%, down from 35%

Capital expenditures

$45 million to $55 million, down from $65 million to $75 million

$45 million to $55 million, down from $65 million to $75 million

Conference Call Information and Forward-Looking Statements
Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for its fiscal 2018 second quarter ended December 31, 2017.  The conference call will be available to interested parties by dialing 800-447-0521 from the U.S. or Canada, or 847-413-3238 from international locations, passcode 46403530.  The call will be broadcast via the Internet at www.lannett.com.  Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software.  A playback of the call will be archived and accessible on the same website for at least three months.

Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company's financial status and performance, regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.

Use of Non-GAAP Financial Measures
This news release contains references to Non-GAAP financial measures, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP).  Management uses these measures internally for evaluating its operating performance.  The Company's management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor's overall understanding of the financial results for the Company's core business.  Additionally, it provides a basis for the comparison of the financial results for the Company's core business between current, past and future periods.  Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP. 

Detailed reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included with this release.

Non-GAAP financial measures exclude, among others, the effects of (1) amortization of purchased intangibles and other purchase accounting entries, (2) acquisition and integration-related expenses, (3) non-cash interest expense, as well as (4) certain other items considered unusual or non-recurring in nature. 

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications – see financial schedule below for net sales by medical indication.  For more information, visit the company's website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance.  Any such statements, including, but not limited to, realizing the expected increase in sales of generic Toprol-XL®, expected benefits of a lower effective tax rate, successfully launching and commercializing recently acquired and previously approved products, and achieving the financial metrics stated in the company's guidance for fiscal 2018, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, including acquired products, and Lannett's estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company's Form 10-K and other documents filed with the Securities and Exchange Commission from time to time.  These forward-looking statements represent the company's judgment as of the date of this news release.  The company disclaims any intent or obligation to update these forward-looking statements.

Contact:

Robert Jaffe


Robert Jaffe Co., LLC


(424) 288-4098

FINANCIAL SCHEDULES FOLLOW

 

LANNETT COMPANY, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)






(Unaudited)







December 31, 2017


June 30, 2017








ASSETS






Current assets:





Cash and cash equivalents

$                   139,862


$       117,737

Investment securities

27,842


27,091

Accounts receivable, net

256,728


204,066

Inventories


135,591


122,604

Prepaid income taxes

1,760


16,703

Other current assets

6,471


6,592

Total current assets

568,254


494,793

Property, plant and equipment, net

258,206


243,148

Intangible assets, net

439,639


453,861

Goodwill



339,566


339,566

Deferred tax assets

30,584


52,753

Other assets


23,146


19,191

TOTAL ASSETS


$                1,659,395


$    1,603,312















LIABILITIES





Current liabilities:





Accounts payable


$                     78,633


$         44,720

Accrued expenses


12,730


12,499

Accrued payroll and payroll-related expenses

16,036


4,833

Rebates payable


48,379


44,593

Royalties payable


5,579


3,015

Restructuring liability

4,581


5,431

Settlement liability


12,000


17,000

Short-term borrowings and current portion of long-term debt

66,845


60,117

Total current liabilities

244,783


192,208

Long-term debt, net

819,220


843,530

Other liabilities


2,596


6,452

TOTAL LIABILITIES

1,066,599


1,042,190

Commitments and contingencies











STOCKHOLDERS' EQUITY




Common stock($0.001 par value, 100,000,000 shares authorized; 37,760,877




 and 37,528,450 shares issued; 37,105,338 and 36,919,296 shares outstanding at




December 31, 2017 and June 30, 2017, respectively)

38


37

Additional paid-in capital

298,337


292,780

Retained earnings


305,053


277,774

Accumulated other comprehensive loss

(347)


(222)

Treasury stock (655,539 and 609,154 shares at December 31, 2017 and June 30, 2017, respectively)

(10,285)


(9,247)

Total stockholders' equity

592,796


561,122

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 

$                1,659,395


$    1,603,312

 

LANNETT COMPANY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(In thousands, except share and per share data)










Three months ended 


Six months ended 


December 31,


December 31,


2017


2016


2017


2016









Net sales

$    184,305


$    170,944


$    339,266


$    332,503

Cost of sales 

88,914


75,154


168,467


145,974

Amortization of intangibles

7,941


7,737


15,678


16,624

Gross profit

87,450


88,053


155,121


169,905

Operating expenses:








Research and development expenses

10,722


9,939


18,131


22,310

Selling, general, and administrative expenses

28,493


18,069


47,531


39,329

Acquisition and integration-related expenses

65


1,027


83


2,418

Restructuring expenses

1,035


1,712


1,562


3,764

Intangible asset impairment charges

-


23,000


-


88,084

Total operating expenses

40,315


53,747


67,307


155,905

Operating income

47,135


34,306


87,814


14,000

Other income (loss):








Investment income

2,325


1,021


3,489


2,048

Interest expense

(20,686)


(23,333)


(41,598)


(46,327)

Other

3,386


(266)


3,135


(263)

Total other loss

(14,975)


(22,578)


(34,974)


(44,542)

Income (loss) before income tax

32,160


11,728


52,840


(30,542)

Income tax expense (benefit)

18,138


3,542


25,561


(9,340)

Net income (loss)

14,022


8,186


27,279


(21,202)

Less: Net income attributable to noncontrolling interest

-


14


-


34

Net income (loss) attributable to Lannett Company, Inc.

$       14,022


$        8,172


$       27,279


$    (21,236)









Earnings (loss) per common share attributable to Lannett Company, Inc.:








     Basic

$           0.38


$          0.22


$           0.74


$        (0.58)

     Diluted

$           0.37


$          0.22


$           0.72


$        (0.58)









Weighted average common shares outstanding:








     Basic

37,066,902


36,810,388


37,029,483


36,754,828

     Diluted

38,290,358


37,676,370


38,087,826


36,754,828

 

 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)



















Three months ended December 31, 2017


Net sales

Cost of
sales

Amortization
of intangibles

Gross
Profit

Gross
Margin %

R&D
expense

SG&A
expense

Acquisition and
integration-
related
expenses

Restructuring
expenses

Operating
income

Other
income
(loss)

Income
before
income tax

Income
tax expense

Net income

Net income
attributable to
noncontrolling
interest

Net income
attributable to
Lannett
Company, Inc.

Diluted
earnings
per share
(i)




GAAP Reported

$     184,305

$     88,914

$     7,941

$     87,450

47%

$     10,722

$     28,493

$               65

$          1,035

$     47,135

$     (14,975)

$     32,160

$    18,138

$         14,022

$                    -

$     14,022

$          0.37

Adjustments:


















Depreciation of Fixed Assets step-up (a)

-

(1,335)

-

1,335


-

-

-

-

1,335

-

1,335

-

1,335

-

1,335


Amortization of intangibles (b)

-

-

(7,941)

7,941


-

(217)

-

-

8,158

-

8,158

-

8,158

-

8,158


Acquisition and integration-related expenses (c)

-

-

-

-


-

-

(65)

-

65

-

65

-

65

-

65


Restructuring expenses (d)

-

-

-

-


-

-

-

(1,035)

1,035

-

1,035

-

1,035

-

1,035


Non-cash interest (e)

-

-

-

-


-

-

-

-

-

4,454

4,454

-

4,454

-

4,454


Litigation settlement gain (f)

-

-

-

-


-

-

-

-

-

(3,500)

(3,500)

-

(3,500)

-

(3,500)


Other (g)

-

-

-

-


-

(7,405)

-

-

7,405

-

7,405

-

7,405

-

7,405


Tax adjustments (h)

-

-

-

-


-

-

-

-

-

-

-

(7,653)

7,653

-

7,653




















Non-GAAP Adjusted

$     184,305

$         87,579

$     -

$     96,726

52%

$     10,722

$     20,871

$                    -

$                -

$     65,133

$     (14,021)

$     51,112

$      10,485

$          40,627

$                    -

$     40,627

$          1.06



















(a)

Relates to depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. ("KUPI") 

(b)

Relates to amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc. 

(c)

Relates to acquisition and integration-related expenses primarily related to the acquisition of KUPI 

(d)

To exclude expenses associated with the 2016 Restructuring Plan 

(e)

To exclude non-cash interest expense primarily associated with debt issuance costs 

(f)

To exclude a settlement gain associated with patent litigation  

(g)

To exclude separation benefits associated with the former Chief Executive Officer as well as a reversal of indemnified unrecognized tax benefits due to expirations in the statute of limitations, related to the KUPI acquisition 

(h)

To exclude the impact of the revaluation of net long term deferred tax assets related to the Tax Cut and Jobs Act legislation ("2017 Tax Reform"), partially offset by the tax effect of the pre-tax adjustments included at applicable tax rates as well as the reversal of indemnified unrecognized tax benefits related to the KUPI acquisition

(i)

The weighted average share number for the three months ended December 31, 2017 is 38,290,358 for both the GAAP and the non-GAAP earnings per share calculations 

 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)




















Three months ended December 31, 2016


Net sales

Cost of
sales

Amortization

of intangibles

Gross
Profit

Gross
Margin %

R&D
expense

SG&A
expense

Acquisition
and integration-
related
expenses

Restructuring
expenses

Intangible
asset
impairment
charge

Operating
income

Other
income
(loss)

Income
before
income
tax

Income tax
expense

Net
income

Net income
attributable to
noncontrolling
interest

Net income
attributable to
Lannett Company,
Inc.

Diluted
earnings per
share (i)




GAAP Reported

$ 170,944

$ 75,154

$        7,737

$ 88,053

52%

$   9,939

$      18,069

$        1,027

$       1,712

$   23,000

$ 34,306

$(22,578)

$    11,728

$   3,542

$  8,186

$               14

$                  8,172

$       0.22

Adjustments:



















Depreciation of Fixed Assets step-up (a)

-

(404)

-

404


-

-

-

-

-

404

-

404

-

404

-

404


Amortization of intangibles (b)

-

-

(7,737)

7,737


-

(365)

-

-

-

8,102

-

8,102

-

8,102

-

8,102


Acquisition and integration-related expenses (c)

-

-

-

-


-

-

(1,027)

-

-

1,027

-

1,027

-

1,027

-

1,027


Restructuring expenses (d)

-

-

-

-


-

-

-

(1,712)

-

1,712

-

1,712

-

1,712

-

1,712


Intangible assets impairment charge (e)

-

-

-

-


-

-

-

-

(23,000)

23,000

-

23,000

-

23,000

-

23,000


Non-cash interest (f)

-

-

-

-


-

-

-

-

-

-

5,403

5,403

-

5,403

-

5,403


Other (g)

-

-

-

-


-

(715)

-

-

-

715

-

715

-

715

-

715


Tax adjustments (h)

-

-

-

-


-

-

-

-

-

-

-

-

13,992

(13,992)

-

(13,992)





















Non-GAAP Adjusted

$   170,944

$   74,750

$              -

$   96,194

56%

$     9,939

$       16,989

$              -

$             -

$           -

$   69,266

$  (17,175)

$     52,091

$   17,534

$  34,557

$                14

$                  34,543

$        0.92




















(a)

 Relates to depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. ("KUPI") 

(b)

 Relates to amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc. 

(c)

 Relates to acquisition and integration-related expenses primarily related to the acquisition of KUPI 

(d)

 To exclude expenses associated with the 2016 Restructuring Plan 

(e)

 To exclude an impairment charge related to certain intangible assets acquired as part of the KUPI acquisition 

(f)

 To exclude non-cash interest expense primarily associated with debt issuance costs 

(g)

 Primarily relates to separation expenses associated with a former employee 

(h)

 The tax effect of the pre-tax adjustments included at applicable tax rates 

(i)

 The weighted average share number for the three months ended December 31, 2016 is 37,676,370 for both the GAAP and the non-GAAP earnings per share calculations 

 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)



















Six months ended December 31, 2017


Net
sales

Cost of
sales

Amortization
of intangibles

Gross
Profit

Gross
Margin %

R&D
expense

SG&A
expense

Acquisition
and integration-
related
expenses

Restructuring
expenses

Operating
income

Other
income
(loss)

Income
before
income tax

Income tax
expense

Net
income

Net income
attributable to
noncontrolling
interest

Net income
attributable to
Lannett Company,
Inc.

Diluted
earnings
per share (i)




GAAP Reported

$      339,266

$        168,467

$         15,678

$  155,121

46%

$     18,131

$ 47,531

$                83

$       1,562

$ 87,814

$   (34,974)

$  52,840

$ 25,561

$   27,279

$             -

$        27,279

$    0.72

Adjustments:


















Depreciation of Fixed Assets step-up (a)

-

(2,670)

-

2,670


-

-

-

-

2,670

-

2,670

-

2,670

-

2,670


Amortization of intangibles (b)

-

-

(15,678)

15,678


-

(582)

-

-

16,260

-

16,260

-

16,260

-

16,260


Acquisition and integration-related expenses (c)

-

-

-

-


-

-

(83)

-

83

-

83

-

83

-

83


Restructuring expenses (d)

-

-

-

-


-

-

-

(1,562)

1,562

-

1,562

-

1,562

-

1,562


Non-cash interest (e)

-

-

-

-


-

-

-

-

-

9,014

9,014

-

9,014

-

9,014


Litigation settlement gain (f)

-

-

-

-


-

-

-

-

-

(3,500)

(3,500)

-

(3,500)

-

(3,500)


Other (g)

-

-

-

-


-

(7,405)

-

-

7,405

-

7,405

-

7,405

-

7,405


Tax adjustments (h)

-

-

-

-


-

-

-

-

-

-

-

(2,530)

2,530

-

2,530




















Non-GAAP Adjusted

$        339,266

$          165,797

$                 -

$    173,469

51%

$       18,131

$  39,544

$                 -

$             -

$ 115,794

$     (29,460)

$    86,334

$  23,031

$     63,303

$              -

$         63,303

$     1.66



















(a)

Relates to depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. ("KUPI") 

(b)

Relates to amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc. 

(c)

Relates to acquisition and integration-related expenses primarily related to the acquisition of KUPI 

(d)

To exclude expenses associated with the 2016 Restructuring Plan 

(e)

To exclude non-cash interest expense primarily associated with debt issuance costs 

(f)

To exclude a settlement gain associated with patent litigation  

(g)

To exclude separation benefits associated with the former Chief Executive Officer as well as a reversal of indemnified unrecognized tax benefits due to expirations in the statute of limitations, related to the KUPI acquisition 

(h)

To exclude the impact of the revaluation of net long term deferred tax assets related to the Tax Cut and Jobs Act legislation ("2017 Tax Reform"), partially offset by the tax effect of the pre-tax adjustments included at applicable tax rates as well as the reversal of indemnified unrecognized tax benefits related to the KUPI acquisition

(i)

The weighted average share number for the six months ended December 31, 2017 is 38,087,826 for both the GAAP and the non-GAAP earnings per share calculations 

 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

(In thousands, except percentages, share and per share data)




















Six months ended December 31, 2016


Net sales

Cost
of sales

Amortization
of intangibles

Gross
Profit

Gross
Margin %

R&D
expense

SG&A
expense

Acquisition
and integration-
related
expenses

Restructuring
expenses

Intangible
asset
impairment
charges

Operating
income

Other
income
(loss)

Income
(loss) before
income tax

Income tax
expense
(benefit)

Net
income
(loss)

Net income
attributable to
noncontrolling
interest

Net income (loss)
attributable to
Lannett Company,
Inc.

Diluted
earnings
(loss) per
share (j)




GAAP Reported

$332,503

$  145,974

$         16,624

$   169,905

51%

$ 22,310

$       39,329

$           2,418

$       3,764

$  88,084

$  14,000

$   (44,542)

$     (30,542)

$ (9,340)

$     (21,202)

$             34

$               (21,236)

$     (0.58)

Adjustments:



















Depreciation of Fixed Assets step-up (a)

-

(1,740)

-

1,740


-

-

-

-

-

1,740

-

1,740

-

1,740

-

1,740


Amortization of Inventory step-up (b)

-

(1,938)

-

1,938


-

-

-

-

-

1,938

-

1,938

-

1,938

-

1,938


Amortization of intangibles (c)

-

-

(16,624)

16,624


-

(730)

-

-

-

17,354

-

17,354

-

17,354

-

17,354


Acquisition and integration-related expenses (d)

-

-

-

-


-

-

(2,418)

-

-

2,418

-

2,418

-

2,418

-

2,418


Restructuring expenses (e)

-

-

-

-


-

-

-

(3,764)

-

3,764

-

3,764

-

3,764

-

3,764


Intangible asset impairment charges (f)

-

-

-

-


-

-

-

-

(88,084)

88,084

-

88,084

-

88,084

-

88,084


Non-cash interest (g)

-

-

-

-


-

-

-

-

-

-

10,273

10,273

-

10,273

-

10,273


Other (h)

-

-

-

-


-

(715)

-

-

-

715

-

715

-

715

-

715


Tax adjustments (i)

-

-

-

-


-

-

-

-

-

-

-

-

41,516

(41,516)

-

(41,516)





















Non-GAAP Adjusted

$332,503

$    142,296

$                 -

$     190,207

57%

$  22,310

$         37,884

$                 -

$             -

$          -

$  130,013

$     (34,269)

$     95,744

$  32,176

$     63,568

$             34

$               63,534

$     1.69




















(a)

 Relates to depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. ("KUPI") 

(b)

 Relates to amortization of a fair value step-up in inventory related to the acquisition of KUPI 

(c)

 Relates to amortization of purchased intangible assets primarily related to the acquisitions of KUPI and Silarx Pharmaceuticals, Inc. 

(d)

 Relates to acquisition and integration-related expenses primarily related to the acquisition of KUPI 

(e)

 To exclude expenses associated with the 2016 Restructuring Plan 

(f)

 To exclude impairment charges related to certain intangible assets acquired as part of the KUPI acquisition 

(g)

 To exclude non-cash interest expense primarily associated with debt issuance costs 

(h)

 Primarily relates to separation expenses associated with a former employee 

(i)

 The tax effect of the pre-tax adjustments included at applicable tax rates 

(j)

 The weighted average share number for the six months ended December 31, 2016 are 36,754,828 and 37,630,069 for the GAAP and non-GAAP earnings (loss) per share calculations, respectively 

 

LANNETT COMPANY, INC.

RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION (UNAUDITED)

($ in millions)




Fiscal Year 2018 Guidance






Non-GAAP


GAAP


Adjustments


Adjusted







Net sales

 $680 - $700 


-


 $680 - $700 

Gross margin percentage

 42.0% - 43.0% 


6%

 (a) 

 48.0% to 49.0% 

R&D expense

 $36 - $38 


-


 $36 - $38 

SG&A expense

 $79 - $81 


($8)

 (b) 

 $71 - $73 

Integration and Restructuring expense

 $4 - $5 


 ($4 - $5) 

 (c) 

-

Interest expense and other

 $77 - $78 


($15)

 (d) 

 $62 - $63 

Effective tax rate

 approx. 39% 


(12%)

 (e)

 approx. 27% 

Capital expenditures

 $45 - $55 


-


 $45 - $55 













(a) The adjustment primarily reflects amortization of purchased intangible assets and depreciation of a fair value step-up in property, plant and equipment related to the acquisition of Kremers Urban Pharmaceuticals, Inc. ("KUPI")

(b) The adjustment primarily reflects severance benefits to the former chief executive officer, a reversal of indemnified unrecognized tax benefits as well as amortization of purchased intangible assets related to the acquisition of KUPI

(c) The adjustment primarily reflects expenses related to the 2016 Restructuring Plan

(d) The adjustment primarily reflects non-cash interest expense associated with debt issuance costs as well as a litigation settlement gain

(e) The adjustment primarily reflects the impact of the revaluation of net long term deferred tax assets related to the Tax Cut and Jobs Act legislation ("2017 Tax Reform")


 

LANNETT COMPANY, INC.

NET SALES BY MEDICAL INDICATION










Three months ended


Six months ended

(in thousands)

December 31, 


December 31, 

Medical Indication

2017


2016


2017


2016

Antibiotic

$    3,552


$    4,792


$    6,900


$    8,572

Anti-Psychosis

22,799


15,365


37,791


32,685

Cardiovascular

10,135


11,975


21,441


24,669

Central Nervous System

6,925


10,555


15,742


20,904

Gallstone

5,282


13,425


11,846


26,308

Gastrointestinal

15,055


18,977


29,608


37,029

Glaucoma

2,164


5,311


4,832


11,095

Migraine

15,484


7,863


30,499


15,023

Muscle Relaxant

3,219


3,004


7,010


6,536

Pain Management

6,128


7,439


11,889


14,047

Respiratory

2,230


2,957


3,876


5,170

Thyroid Deficiency

68,794


45,431


116,008


85,269

Urinary

2,840


4,693


5,837


9,794

Other

13,105


11,133


25,802


22,314

Contract Manufacturing revenue

6,593


8,024


10,185


13,088

   Net Sales

$ 184,305


$ 170,944


$ 339,266


$ 332,503

 

SOURCE Lannett Company, Inc.


print email rss
Lannett Investor Relations
Lannett Company Products